Patrick Patterson
Corneal and Contact Management · Beaufort, NCNPI 1306891015
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,501 of the $5,781 with a category attached, or 60.6%. 14 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 40.0% of the total. Reporting peaked in 2023 at $3,260 and has fallen 85.2% since, to $481 in 2025.
Across 89 payments — averaging $64.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Johnson & Johnson Vision Care, Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$505
- Bausch & Lomb Americas Inc.$502
- Alcon$375
- Glaukos Corporation$338
- plus $523 from 8 others
What the payments were for
- Food & beverage$3,50161%
- Entertainment$591%
- Other$2,22138%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 3 | $2,315 |
| Johnson & Johnson Vision Care, Inc. | 26 | $1,223 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $505 |
| Bausch & Lomb Americas Inc. | 18 | $502 |
| Alcon | 8 | $375 |
| Glaukos Corporation | 4 | $338 |
| Sun Pharmaceutical Industries Inc. | 2 | $141 |
| Coopervision Inc. | 5 | $107 |
| Optos, Inc. | 2 | $94 |
| Ocular Therapeutix, Inc. | 1 | $54 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Staar Surgical Company | 1 | $39 |
| Novartis | 2 | $30 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few corneal and contact management providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 29 | $9,508 |
| Restasis MultidoseCyclosporine | 14 | $8,594 |
| XiidraLifitegrast | 12 | $8,448 |
| RestasisCyclosporine | 13 | $8,136 |
| LumiganBimatoprost | 16 | $5,583 |
| Loteprednol Etabonate | 28 | $3,784 |
| Travoprost | 16 | $3,476 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 55 | $2,540 |
| Alphagan PBrimonidine Tartrate | 11 | $2,158 |
| Latanoprost | 158 | $1,889 |
| Timolol Maleate | 52 | $1,478 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $239 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $502 | $8,44812 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $505 | $3,78428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few corneal and contact management providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other corneal and contact management in Beaufort
- Chantel Garcia TarbettHarrisburg$48K
- Hiten PrajapatiMorrisville$7K
- Melissa HeislerWinston Salem$3K
- Jean ParkerGreensboro$3K
- Kelly ReidWinston Salem$3K
- Jingya ChenGreensboro$2K
- Linda StolfoRaleigh$2K
- Lisa DavisWinston Salem$801
- Roger DavisWinston Salem$690
- Billy CashWinston-Salem$350
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.